Integra LifeSciences: FDA Warning, Recalls, and Stock Drop

Integra LifeSciences plunges after an FDA warning letter reveals critical lapses in product control at its Boston facility, triggering investor unease and casting doubt on when the company can resume selling tissue products. This latest setback, following a recent global recall and production halt, has shares spiraling, leaving investors to question if this dip is a buying opportunity or a red flag. Hosted on Acast. See acast.com/privacy for more information.